Search research articles
Contact Us
Filters
Showing results (151-160 of 168) with videos related to
Page
of 17
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 10, 2019
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial
W Shi, T Jiang, P Nuciforo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 9, 2017
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial
W Shi, T Jiang, P Nuciforo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 28, 2018
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial
W Shi, T Jiang, P Nuciforo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 19, 2014
Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†
M Piccart, G N Hortobagyi, M Campone, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 30, 2010
Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM)
R Colomer, E Alba, A González-Martin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 16, 2017
Oncologist use and perception of large panel next-generation tumor sequencing
A M Schram, D Reales, J Galle, et al.
British Journal of Cancer
|
September 17, 2014
The AURORA initiative for metastatic breast cancer
D Zardavas, M Maetens, A Irrthum, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 14, 2000
Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group
J Bellmunt, V Guillem, L Paz-Ares, et al.
Breast Cancer Research and Treatment
|
June 17, 2016
Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study
L M Smyth, N M Iyengar, M F Chen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 12, 2017
The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO
S Di Cosimo, C Campbell, H A Azim, et al.
Page
of 17
Search research articles
Search
Showing results (151-160 of 168) with videos related to
Sort By:
Page
of 17
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 10, 2019
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial
W Shi, T Jiang, P Nuciforo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 9, 2017
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial
W Shi, T Jiang, P Nuciforo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 28, 2018
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial
W Shi, T Jiang, P Nuciforo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 19, 2014
Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†
M Piccart, G N Hortobagyi, M Campone, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 30, 2010
Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM)
R Colomer, E Alba, A González-Martin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 16, 2017
Oncologist use and perception of large panel next-generation tumor sequencing
A M Schram, D Reales, J Galle, et al.
British Journal of Cancer
|
September 17, 2014
The AURORA initiative for metastatic breast cancer
D Zardavas, M Maetens, A Irrthum, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 14, 2000
Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group
J Bellmunt, V Guillem, L Paz-Ares, et al.
Breast Cancer Research and Treatment
|
June 17, 2016
Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study
L M Smyth, N M Iyengar, M F Chen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 12, 2017
The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO
S Di Cosimo, C Campbell, H A Azim, et al.
Page
of 17